MX2018015343A - Anticuerpo neutralizante contra el dengue para uso en un método de prevención y/o tratamiento de la infección por zika. - Google Patents
Anticuerpo neutralizante contra el dengue para uso en un método de prevención y/o tratamiento de la infección por zika.Info
- Publication number
- MX2018015343A MX2018015343A MX2018015343A MX2018015343A MX2018015343A MX 2018015343 A MX2018015343 A MX 2018015343A MX 2018015343 A MX2018015343 A MX 2018015343A MX 2018015343 A MX2018015343 A MX 2018015343A MX 2018015343 A MX2018015343 A MX 2018015343A
- Authority
- MX
- Mexico
- Prior art keywords
- residues
- zika
- denv
- flaviviruses
- virus
- Prior art date
Links
- 208000020329 Zika virus infectious disease Diseases 0.000 title abstract 6
- 208000001490 Dengue Diseases 0.000 title abstract 4
- 206010012310 Dengue fever Diseases 0.000 title abstract 4
- 208000025729 dengue disease Diseases 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 241000710831 Flavivirus Species 0.000 abstract 12
- 241000907316 Zika virus Species 0.000 abstract 7
- 239000000539 dimer Substances 0.000 abstract 5
- 239000000178 monomer Substances 0.000 abstract 5
- 241000725619 Dengue virus Species 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000000833 heterodimer Substances 0.000 abstract 2
- 239000000710 homodimer Substances 0.000 abstract 2
- 239000004971 Cross linker Substances 0.000 abstract 1
- 101710126499 Envelope glycoprotein E Proteins 0.000 abstract 1
- 108010075717 Flavivirus glycoprotein E Proteins 0.000 abstract 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 abstract 1
- 101000972637 Homo sapiens Protein kintoun Proteins 0.000 abstract 1
- 102100022660 Protein kintoun Human genes 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
Un epítopo de dímero de envoltura (EDE) de flavivirus para su uso en la vacunación de un individuo contra uno o más flavivirus. en donde el EDE es un flavivirus recombinante estabilizado, opcionalmente un dímero de ectodominio (sE) de glicoproteína E de la envoltura del virus del dengue y/o virus del Zika, en donde el dímero está: estabilizado de manera covalente con al menos un puente disulfuro intercatenario entre los dos monómeros de sE y/o estabilizado de manera no covalente mediante la sustitución de al menos un residuo de aminoácidos en la secuencia de aminoácidos de al menos un monómero de sE con al menos un aminoácido de cadena lateral voluminosa, en la interfaz de dímero o en el ligador de dominio 1 (D1)/dominio 3 (D3) de cada monómero, estabilizado de manera covalente con al menos un reticulador reactivo con sulfhidrilo entre los dos monómeros de sE, y/o estabilizado de manera covalente al formarse como una única cadena de polipéptidos, opcionalmente con una región ligadora, opcionalmente una región ligadora rica en glicina-serina, que separa las secuencias de sE y/o estabilizado de manera covalente mediante la unión de los dos monómeros de sE a través de azúcares modificados; y/o en donde el dímero es un homodímero o heterodímero de polipéptidos de envoltura nativos y/o mutantes, de uno o dos de DENV-1, DENV-2, DENV-3, DENV-4, Zika u otro flavivirus; y en donde el uno o más flavivirus se seleccionan del virus del Zika; virus del Zika y virus del dengue; virus del Zika y otros flavivirus; flavivirus distintos del dengue. El EDE puede ser un homodímero o heterodímero de polipéptidos de envoltura nativos y/o mutantes, de uno o dos de DENV-1, DENV-2, DENV-3, DENV-4 y Zika. Un anticuerpo neutralizante aislado o un fragmento de fijación a antígeno de este dirigido contra el EDE como se define en cualquiera de las reivindicaciones 1 a 29, en donde opcionalmente dicho anticuerpo o fragmento de este se fija a los cinco segmentos de polipéptidos del ectodominio E de glicoproteína del virus del dengue que consiste en los residuos 67-74, los residuos 97-106, los residuos 307-314, los residuos 148-159 y los residuos 243-251, o residuos correspondientes del ectodominio E (sE) de glicoproteína del flavivirus o virus del Zika, o que consiste en residuos de Zika PF13 67-77, los residuos 97-106, los residuos 313-315, los residuos 243-253, el residuo K373 o residuos correspondientes del ectodominio (sE) de glicoproteína E del flavivirus, opcionalmente en donde la fijación no se ve afectada por la presencia o ausencia de glicano de dengue N153 (Zika N154) o un correspondiente residuo, para uso en un método para la prevención y/o el tratamiento de infección por uno o más flavivirus, en donde el uno o más flavivirus se seleccionan de virus del Zika; virus del Zika y virus del dengue; virus del Zika y otros flavivirus; flavivirus distintos del dengue.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1610162.8A GB201610162D0 (en) | 2016-06-10 | 2016-06-10 | Methods |
| PCT/GB2017/051692 WO2017212291A1 (en) | 2016-06-10 | 2017-06-09 | Neutralising antibody against dengue for use in a method of prevention and/or treatment of zika infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018015343A true MX2018015343A (es) | 2019-11-18 |
Family
ID=56894660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015343A MX2018015343A (es) | 2016-06-10 | 2017-06-09 | Anticuerpo neutralizante contra el dengue para uso en un método de prevención y/o tratamiento de la infección por zika. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11111274B2 (es) |
| EP (1) | EP3468591A1 (es) |
| JP (1) | JP2019523647A (es) |
| BR (1) | BR112018075396A2 (es) |
| CA (1) | CA3066488A1 (es) |
| GB (1) | GB201610162D0 (es) |
| MX (1) | MX2018015343A (es) |
| WO (1) | WO2017212291A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR068563A1 (es) | 2007-09-26 | 2009-11-18 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo mutante |
| KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| AU2018359556B2 (en) | 2017-11-03 | 2021-12-02 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| KR20200094191A (ko) | 2017-11-30 | 2020-08-06 | 다케다 백신즈 인코포레이티드 | 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들 |
| CN116327926A (zh) * | 2018-03-15 | 2023-06-27 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
| US20210308250A1 (en) * | 2018-10-26 | 2021-10-07 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
| JP7221995B2 (ja) * | 2019-05-28 | 2023-02-14 | チェンマイ・ユニバーシティ | フラビウイルスの成熟ウイルス様粒子 |
| TWI756812B (zh) * | 2019-09-03 | 2022-03-01 | 財團法人國家衛生研究院 | 廣效性蚊媒黃病毒疫苗及其用於誘發中和性抗體的用途 |
| JP7471555B2 (ja) * | 2020-02-20 | 2024-04-22 | 国立感染症研究所長 | フラビウイルス交差中和抗体及び医薬組成物 |
| WO2023235660A2 (en) * | 2022-05-17 | 2023-12-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Flavivirus immunogens and vaccine compositions and methods of using the same |
| WO2024081625A1 (en) * | 2022-10-11 | 2024-04-18 | University Of Maryland, Baltimore | Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| IN2012DN03294A (es) | 2004-07-27 | 2015-10-23 | Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And | |
| CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| GB201413086D0 (en) * | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
-
2016
- 2016-06-10 GB GBGB1610162.8A patent/GB201610162D0/en not_active Ceased
-
2017
- 2017-06-09 JP JP2018564238A patent/JP2019523647A/ja active Pending
- 2017-06-09 BR BR112018075396-3A patent/BR112018075396A2/pt unknown
- 2017-06-09 EP EP17737013.7A patent/EP3468591A1/en active Pending
- 2017-06-09 US US16/308,745 patent/US11111274B2/en active Active
- 2017-06-09 MX MX2018015343A patent/MX2018015343A/es unknown
- 2017-06-09 CA CA3066488A patent/CA3066488A1/en active Pending
- 2017-06-09 WO PCT/GB2017/051692 patent/WO2017212291A1/en unknown
-
2021
- 2021-04-27 US US17/241,884 patent/US11926648B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190256560A1 (en) | 2019-08-22 |
| US11111274B2 (en) | 2021-09-07 |
| EP3468591A1 (en) | 2019-04-17 |
| JP2019523647A (ja) | 2019-08-29 |
| US11926648B2 (en) | 2024-03-12 |
| WO2017212291A1 (en) | 2017-12-14 |
| BR112018075396A2 (pt) | 2019-03-19 |
| CA3066488A1 (en) | 2017-12-14 |
| US20210355167A1 (en) | 2021-11-18 |
| GB201610162D0 (en) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018015343A (es) | Anticuerpo neutralizante contra el dengue para uso en un método de prevención y/o tratamiento de la infección por zika. | |
| EP4223773A3 (en) | Methods | |
| MX2016008539A (es) | Variantes de region fc con propiedades de union a receptor fc neonatal (fcrn) modificadas y de union a proteina a mantenidas. | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| CO2017004318A2 (es) | Variantes de interferon α2b | |
| NZ724904A (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| BR112013008407A2 (pt) | antígenos de clostridium difficile | |
| BR112016016411A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS | |
| ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
| AR094149A1 (es) | Proteinas multifuncion que comprenden chm de clase i multivalente unido mediante disulfuro | |
| UA108778C2 (xx) | Протираковий злитий протеїн | |
| AR086199A1 (es) | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos | |
| MX2020011391A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| PH12016501937A1 (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| MX2019003890A (es) | Anticuerpos con union reducida a impurezas de proceso. | |
| CL2017003228A1 (es) | Fragmentos mutantes de proteína ras | |
| WO2013150309A8 (en) | Clostridium difficile antigens | |
| UA117493C2 (uk) | Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання | |
| MX2019002178A (es) | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). | |
| PH12021550082A1 (en) | Fcrn antibody compositions | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| GB2543713A (en) | Polymeric proteins and uses thereof | |
| PE20181956A1 (es) | Polipeptidos que inhiben cd40l |